Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Spring;15(2):80-4.
doi: 10.7812/TPP/10-140.

Acute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report

Acute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report

Robert G Bota et al. Perm J. 2011 Spring.

Abstract

Valproic acid (VPA) is an antiepileptic medication used in the treatment of bipolar disorder. Its toxicity profile is characterized by a very rare but well-documented complication-hepatotoxicity. The risk of acute hypersensitivity syndrome (AHS) caused by VPA is less well known. In the vast majority of reported cases of AHS, the syndrome is the result of aromatic anticonvulsants (AAs), such as carbamazepine or phenytoin. These compounds also have in-class cross-reactivity. We present the case of a 25-year-old woman with bipolar disorder who was unable to tolerate aripiprazole, ziprasidone, and lamotrigine. She was given extended-release VPA as a trial and developed AHS with a generalized rash, fever, liver and kidney involvement, and eosinophilia one week after the initiation of treatment. She recovered after one month of treatment, which included ten days of hospitalization. Our review of the literature focuses on AA and non-AA medications causing AHS.

PubMed Disclaimer

References

    1. Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem. 1988 May;34(5):890–7. - PubMed
    1. Binek J, Hany A, Egloff B, Heer M. [Acute fatal liver insufficiency due to valproic acid therapy]. [Article in German] Schweiz Med Wochenschr. 1991 Feb 16;121(7):228–33. - PubMed
    1. Bell EA, Shaefer MS, Markin RS, et al. Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation. Ann Pharmacother. 1992 Jan;26(1):18–21. - PubMed
    1. Fisher RL, Sanuik JT, Nau H, Gandolfi AJ, Brendel K. Comparative toxicity of valproic acid and its metabolites in liver slices from adult rats, weanling rats and humans. Toxicol In Vitro. 1994 Jun;8(3):371–9. - PubMed
    1. de Wolff FA, Peters AC, van Kempen GM. The effects of valproic acid on liver function. Arch Toxicol Suppl. 1983;6:369–73. - PubMed

LinkOut - more resources